Immunic (IMUX) Restructuring Costs (2018 - 2019)

Immunic (IMUX) reported Restructuring Costs of $6.4 million for Q1 2019, up 165.93% sequentially from $2.4 million in Q3 2018.

Immunic (IMUX) Restructuring Costs (2018 - 2019) Analysis & Trends

Immunic (IMUX) has 2 years of Restructuring Costs data on file, last reported at $6.4 million in Q1 2019.

For the quarter ending Q1 2019, Restructuring Costs changed N/A year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2019 stood at $8.8 million (changed N/A YoY), and the FY2018 full-year result was $2.4 million, changed N/A from the prior year.
Restructuring Costs improved to $6.4 million in Q1 2019, from $2.4 million in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $6.4 million in Q1 2019 to a low of $2.4 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Immunic	11.03 Mn	11.03 Mn	-

Download Data

Date	Value
Mar 31, 2019	6.37 Mn
Sep 30, 2018	2.40 Mn